1 Big Question Facing Moderna in 2022
Moderna (NASDAQ: MRNA) has gone from a relatively unknown stock a few years ago to a business that's worth more than $85 billion thanks to its COVID-19 vaccine. Many investors have earned great returns on the stock, which soared 143% last year, blowing past the S&P 500's 27% return.
But whether it's a good buy today is more of a question mark. And that's because its future post-COVID is uncertain. How much revenue it might generate and which products it will rely on for growth when the pandemic is over are just a few of the things long-term investors will want to know. And the key to answering that may rest with what the healthcare company decides to do on a more immediate issue.
Image source: Getty Images.
Source Fool.com
